pirfenidone has been researched along with sb 525334 in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cao, X; Gao, S; Guo, Y; Huang, M; Li, X; Liu, S; Xie, C; Zhai, Y; Zhou, H | 1 |
| Chen, X; Hou, J; Jiang, H; Liao, Y; Liao, Z; Liu, P; Wang, E; Wang, L; Wang, X; Wu, X; Xu, X | 1 |
2 other study(ies) available for pirfenidone and sb 525334
| Article | Year |
|---|---|
In vitro screening for compounds from Hypericum longistylum with anti-pulmonary fibrosis activity.
Topics: Animals; Antifibrinolytic Agents; Cell Survival; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Fibroblasts; Hypericum; Mice; Molecular Structure; Plant Extracts; Pulmonary Fibrosis; Signal Transduction; Smad3 Protein; Structure-Activity Relationship; Transforming Growth Factor beta1 | 2019 |
A combination of pirfenidone and TGF-β inhibition mitigates cystic echinococcosis-associated hepatic injury.
Topics: Animals; Echinococcosis, Hepatic; Imidazoles; Liver; Mice; Pyridones; Quinoxalines; Transforming Growth Factor beta1 | 2021 |